On Jan. 2, Hookipa inked a non-binding agreement that would have created a merged company with Poolbeg via an all-stock ...

In a turbulent market environment, Vincerx Pharma, Inc. (VINC) stock has reached its 52-week low, trading at $1.3. According to InvestingPro analysis, the company maintains a healthy current ratio of ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Vincerx Pharma, Inc. (Nasdaq: VINC) today announced promising clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through ...